Molecular Response and Scripps Genomic Medicine Announce Joint Discovery/Development Agreement

SAN DIEGO--(BUSINESS WIRE)-- Molecular Response (MRL), a privately held molecular diagnostic services company and a leader in the identification of target populations for high value therapeutics, announced today a joint discovery/development agreement with Scripps Genomic Medicine that will advance research in the areas of oncology and cardiovascular disease.

“This agreement is a great opportunity to collaborate with one of the nation’s leading healthcare institutes, where many cutting-edge scientific research and development initiatives have emerged,” said Cyrus K. Mirsaidi, Molecular Response CEO. “We look forward to significant diagnostic and therapeutic advances stemming from this partnership.”

Under the terms of the agreement, Molecular Response will fund up to two discovery programs focusing on cancer research and heart disease. Additionally, MRL will be granted exclusive intellectual property rights with Scripps Genomic Medicine, a division of Scripps Translational Science Institute and Scripps Health. Additional terms of the agreement were not disclosed.

“For us to individualize prevention and treatment with precision, we are fortunate to set up this important collaboration with Molecular Response,” said Dr. Eric Topol, Chief Academic Officer of Scripps Health. “Medicine tailored to an individual, particularly with the application of genomics, will ultimately have a major impact in the future of health care.”

The alliance builds on strong scientific commitment from both organizations, and will encourage and support research collaboration that will provide access to technologies and knowledge that will expand the partnership’s overall research activities.

About Molecular Response

Molecular Response is a leader in advancing targeted therapeutics through intelligently designed, clinically validated companion diagnostics. Our goal is to reduce risk and cost of therapeutic drug development for our partners by translating clinically relevant molecular response marker data into high-value knowledge while fully integrated into existing pharmaceutical development processes and programs; Our results reduce risk and cost of drug development and allow for the most informed decisions with best chance of success to advance therapeutic programs.

For additional information please visit www.molecularresponse.com.

About Scripps Translational Science Institute:

Founded in 2006, Scripps Translational Science Institute (STSI) is an initiative of Scripps Health, in collaboration with The Scripps Research Institute. STSI initiates research designed to help move basic research from lab to the patient bedside, bridging the gap between basic science and clinical trials. Scripps Genomic Medicine is a program of STSI and involves genotyping tens of thousands of individuals to identify and define genes responsible for major diseases and the underpinnings of health.

For additional information please visit www.stsiweb.org.



CONTACT:

Molecular Response
Sandra Hazeltine, 858.204.3540
[email protected]

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Cardiology  Genetics  Oncology  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.